Dr Stock on ASH Guidelines for Asparaginase-Based Regimens in AYA ALL

[The guidelines] try to address issues of pre-medication [with asparaginase-based therapy], issues of dosing, issues of toxicity management, and alternative approaches for hypersensitivity reactions.

Wendy Stock, MD, the Anjuli Seth Nayak Professor of Medicine at University of Chicago Medicine and co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center, discusses recommendations from the ASH Guidelines on utilizing pediatric-inspired, asparaginase-based regimens in the treatment of adolescent/young adult (AYA) patients with acute lymphoblastic leukemia (ALL).

In February 2026, ASH released its 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults, which were generated by a multidisciplinary panel featuring hematologists, AYA psychosocial care specialists, pharmacists, methodologists, and patient representatives, with the goal of supporting frontline treatment decisions for this patient population.

In the guidelines, pediatric-inspired asparaginase-based therapies are recommended as frontline therapy compared with traditional adult-inspired treatment regimens, with mandates for significant supportive care and close follow-up when utilizing these treatments. The use of prophylactic premedication to prevent hypersensitivity reactions received a strong recommendation. The panel also recommended against the routine use of unfractionated heparin for venous thromboembolism prophylaxis and against the routine use of cryoprecipitate replacement (or fibrinogen concentrate) outside the context of active bleeding. Switching patients to an erwinia-based asparaginase formulation rather than the discontinuation of asparaginase therapy was recommended for those who experience asparaginase-related allergic/hypersensitivity reactions with pegaspargase (Oncaspar).

Stock explained that recommendations were formulated based on the strength and availability of existing evidence, with the goal of providing practical guidance for clinicians treating the AYA population. In several areas, insufficient evidence precluded the development of firm, evidence-based recommendations. In such cases, the guidelines instead outlined the rationale behind the absence of definitive guidance and summarized the available data used to inform them.

Stock noted that when formal recommendations could not be made, the inclusion of background context and discussion aimed to support clinical decision-making and highlight areas where further research is needed.